Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma

por O'Connor, O A
Publicado 2006

P1278: ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T-C...

por Manavalan, J. S., Pal, I., Pursley, A., Ward, G., Smyth, T., Sims, M., Feith, D., Loughran, T. P., O’Connor, O. A., Marchi, E.
Publicado 2022

The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study

por Zhang, Wei, Su, Liping, Liu, Lihong, Gao, Yuhuan, Wang, Quanshun, Su, Hang, Song, Yuhuan, Zhang, Huilai, Shen, Jing, Jing, Hongmei, Wang, Shuye, Cen, Xinan, Liu, Hui, Liu, Aichun, Li, Zengjun, Luo, Jianmin, He, Jianxia, Wang, Jingwen, O’Connor, O. A., Zhou, Daobin
Publicado 2021

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

por Horwitz, S., O’Connor, O. A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K. J., Yuen, S., Zinzani, P. L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M., Illidge, T.
Publicado 2022